Oxy taps Houston startup's carbon negative biotechnology for new pilot plant

sustainability moves

Cemvita Factory is working on a pilot plant with Oxy to scale its biotechnology. Photo via OxyLowCarbon.com

Occidental's venture arm — Oxy Low Carbon Ventures — has announced its plans to construct and operate a one metric ton per month bio-ethylene pilot plant featuring Houston-based Cemvita Factory's technology that biomimics photosynthesis to convert carbon dioxide into feedstocks.

The new plant will scale the process, which was jointly developed between Cemvita and OLCV, and is expected sometime next year, according to a press release from Oxy.

"Today bio-ethylene is made from bio-ethanol, which is made from sugarcane, which in turn was created by photosynthesizing CO2. Our bio-synthetic process simply requires CO2, water and light to produce bio-ethylene, and that's why it saves a lot of cost and carbon emissions," says Moji Karimi, co-founder and CEO of Cemvita Factory, in the release. "This project is a great example of how Cemvita is applying industrial-strength synthetic biology to help our clients lower their carbon footprint while creating new revenue streams."

Oxy and Cemvita have been working together for a while, and in 2019, OLCV invested an undisclosed amount into the startup. The investment, according to the release, was made to jointly explore how these advances in synthetic biology can be used for sustainability efforts in the bio-manufacturing of OxyChem's products.

"This technology could provide an opportunity to offer a new, non-hydrocarbon-sourced ethylene product to the market, reducing carbon emissions, and in the future benefit our affiliate, OxyChem, which is a large producer and consumer of ethylene in its chlorovinyls business," says Robert Zeller, vice president of technology at OLCV, in a news release.

Moji Karimi founded the company with his sister and Cemvita CTO, Tara, in 2017. The idea was to biomimic photosynthesis to take CO2 and turn it into something else. The first iteration of the technology turned CO2 into sugar — the classic photosynthesis process. Karimi says the idea was to create this process for space, so that astronauts can turn the CO2 they breathe out into a calorie source.

"Nature provided the inspiration," noted Dr. Tara Karimi, co-founder and CTO of Cemvita Factory. "We took a gene from a banana and genetically engineered it into our CO2-utilizing host microorganism. We are now significantly increasing its productivity with the goal to achieve commercial metrics that we have defined alongside OLCV."

A couple weeks ago, Moji Karimi joined the Houston Innovators Podcast to discuss growth and challenges Cemvita Factory faced.

"We're defining this new category for application of synthetic biology in heavy industries for decarbonization," he shares on the show. Stream the episode below.
In the latest round up of Houston innovation news you may have missed, local venture groups announce new investments, Houston schools launch programs, and more. Photo via UH.edu

University of Houston engineers recognized, TMCx company raises funds, and more local innovation news

short stories

It's been a horrific week for both the city of Houston and the state of Texas. Millions of residents have lost power and/or water due to a winter storm that brought low temps. For this reason, Houston innovation news may have fallen through some of the cracks.

In this roundup of short stories within Houston innovation, the Texas Medical Center's Venture Fund and Chevron Technology Ventures make new investments, University of Houston professors make big moves, both Rice University and UH announce new programs, and more.

TMCx company raises $2 million

The Texas Medical Center Venture Fund announced its latest investment. Noninvasix Inc., a startup working on novel precision oximetry technology announced it has closed an over-subscribed seed round at $2 million led by the TMC Venture Fund with support from Philips and GPG Ventures. The funds will help the company advance product development and attain FDA clearance.

"TMC Venture Fund has been a strong supporter of Noninvasix since our initial investment in the company, and we look forward to our continued partnership with them," says Tom Luby, director of TMC Innovation, in a news release. "The potential of this platform technology to guide better clinical decision-making and improve outcomes has us excited to be part of the effort that brings the optoacoustic technology to the market."

The Noninvasix team has created a solution for the safe, accurate and non-invasive monitoring of infant welfare in the neonatal intensive care unit.

"Brain hypoxia, characterized by restricted blood flow to the brain, accounts for 23 percent of all neonatal deaths worldwide and costs the U.S. healthcare system over $7 billion per year, making the development of an accurate and precise patient monitoring system a top maternal-fetal health priority," says Noninvasix CEO Graham Randall, in the release.

"Noninvasix's novel solution utilizes optoacoustic monitoring of cerebral venous oxygenation to accurately measure the adequacy of the oxygen supply to a baby's brain in real time."

The Cannon and the University of Houston launch new partnership

A UH program has teamed up with a local startup development organization. Photo courtesy of The Cannon

The Cannon has partnered up with the Wolff Center for Entrepreneurship at the University of Houston to launch a semester-long program that will introduce students to the Startup Development Organization Network.Through the new collaboration, students will have access to new opportunities to interact and connect with professionals and advisers.

"We couldn't be prouder to partner with the University of Houston and the Wolff Center for Entrepreneurship to engage with the students that will soon be driving innovation in Houston and beyond," says Jon Lambert, CEO of The Cannon, in a news release. "UH is widely recognized for its excellence in entrepreneurial education and what Dave Cook and his team have built through The Wolff Center is second to none.

"The Cannon is excited for the opportunity to play a role in enhancing the entrepreneurial education journey through helping to provide a bridge between world-class academic programming and the commercial entrepreneurial landscape."

Students at WCE will receive access to The Cannon's online platform, Cannon Connect, as well as access to exclusive events hosted by The Cannon.

Rice University launches new data science program

Rice University is now offering a master's in data science beginning in the fall. Photo courtesy of Rice

Rice University has announced it's creating a Master of Data Science program. The degree is offered through the George R. Brown School of Engineering and managed by the Department of Computer Science. With classes beginning in the fall, applications are now open.

"The field of data science touches almost every industry in our economy," says Scott Rixner, a professor in the Rice's Department of Computer Science, in a press release. "This degree will provide those seeking to find new careers, or to advance in their current careers, the opportunity to acquire an indispensable skill set and to build future-focused critical expertise that will drive future innovation."

The 31-credit program will be offer classes both online and face-to-face, according to the release. The courses will deliver the skills needed to collect, evaluate, interpret and present data for effective decision-making across a variety of industries. The new program joins the online Master of Computer Science degree that was launched in 2019.

"Data science has revolutionized all fields of study and many sectors of the industry where data is central to the scientific or industrial endeavor," says Rice Dean of Engineering Luay Nakhleh, in the release. "Data-driven discovery has complemented hypothesis-driven discovery, and it is here to stay. This degree positions our students for rewarding, life-long careers that provide meaningful impact in design and research in a multitude of industries."

Houston biotech company with COVID-19 treatment enters agreement with UH

A UH-founded biotech company has a new partnership to announce. Image via Getty Images

AuraVax Therapeutics Inc. has entered into an exclusive license agreement with the University of Houston for its intranasal vaccine and therapeutics technology platform. The biotech company is developing novel intranasal vaccines and therapies to help patients defeat debilitating diseases including COVID-19. This new agreement upgrades the optioned intellectual property between UH and AuraVax announced in October.

The vaccine is a nasal inhalant, similar to FluMist, and was developed by Navin Varadarajan, an M.D. Anderson professor of chemical and biomolecular engineering at UH. Varadarajan is a co-founder of AuraVax.

"We are excited to rapidly expand our relationship with the University of Houston to advance the development of this novel intranasal approach to tackle respiratory viruses. We plan to stop COVID-19 at its point of entry — the nasal cavity — and we believe our intranasal platform represents a differentiated solution that will lead to a vaccine to create sustained immunity to COVID-19 and other viruses," says Varadarajan, in the news release.

Chevron Technology Ventures makes latest investment

CTV has recently invested in a geothermal energy company. Photo via eavor.com

Houston-based Chevron Technology Ventures has announced its latest investment in Eavor Technologies Inc., a Canadian company that closed a $40 million funding round. Eavor is working on a scalable geothermal technology and hopes to power the equivalent of 10 million homes by 2030.

Eavor-Loop™, Eavor's technology, uses the natural heat of the earth like a battery and is different from what's on the market because of its scalable and transportatable application — as well as because it produces zero emissions.

Along with CTV, investors included bp Ventures, Temasek, BDC Capital, Eversource1, and Vickers Venture Partners.

"I am delighted that with the funding closed in this round we can look forward to bringing down the cost of clean, dispatchable power to a universally competitive level – an important milestone for renewable energy," says John Redfern, president and CEO of the company, in a news release. "The involvement of companies such as bp and Chevron represents a fantastic endorsement of our technology, the progress we have made to date and the promise for its global scalability."

3 UH engineers named to Academy of Inventors

Three UH engineers have been named senior members of the National Academy of Inventors. Photos via UH.edu

The National Academy of Inventors have named three University of Houston Cullen College of Engineering researchers senior members for 2021.

Hien Nguyen, assistant professor of electrical and computer engineering; Jeffrey Rimer, Abraham E. Dukler Endowed Chair, William A. Brookshire Department of Chemical and Biomolecular Engineering; and Gangbing Song, Moores Professor of Mechanical Engineering, are among the 61 selected for the distinguishment, according to a press release from UH.

"This national distinction honoring the research and scholarship of Drs. Nguyen, Rimer and Song is emblematic of the reputation for innovation fostered at the Cullen College of Engineering," says Paula Myrick Short, senior vice president for academic affairs and provost at UH, in the release. "I congratulate these three outstanding faculty members for this well-deserved recognition."

Nguyen works with biomedical data analysis and artificial intelligence, Rimer's expertise in the processes behind crystal growth and formation, and Song researches the development of actuator systems for aerospace, biomedical and oil exploration applications.

A full list of NAI Senior Members is available on the NAI website.

Aziz Gilani to be recognized nationally

A Houston investor is being recognized nationally. Photo va mercuryfund.com

Aziz Gilani, managing director at Houston-based Mercury Fund, was just selected for an award from the National Venture Capital Association. Gilani is being recognized with the Outstanding Service Award for his work last year outlining and explaining the Paycheck Protection Program from the Small Business Administration to entrepreneurs.

The award will be presented at NVCA's virtual ceremony on March 9. More info on the award ceremony here.

A biotech startup focused on developing therapeutics for neurodegenerative and autoimmune diseases has some big news to share. Photo via Getty Images

Houston biotech startup announces merger and $10M series A

getting ahead

A Houston company has emerged from stealth mode to announce a merger and a round of financing.

Coya Therapeutics, a clinical-stage biotech startup that focuses on creating therapeutics for neurodegenerative and autoimmune diseases, announced that it has completed a merger with Nicoya Health Inc. and raised $10 million in its series A. The round was led by Florida-based Allele Capital Partners LLC. Howard Berman, founder and board of directors for imaware, has been named CEO of Coya, as well as a member of the company's board of directors.

Coya's therapeutics uses innovative work from Dr. Stanley H. Appel, co-director of Houston Methodist Neurological Institute and Chair of the Stanley H. Appel Department of Neurology at Houston Methodist Hospital. The researcher has created a way to "isolate dysfunctional Tregs from a patient, convert them to a highly functional and neuroprotective condition, and expand these cells into the billions for intravenous reinfusion back to the patient," says Berman in a news release. This revolutionary work overcomes previous limitations in the field.

"I'm excited to have the opportunity to lead Coya at such an exciting and pivotal phase of growth," Berman says. "Through our sponsored research program in conjunction with Dr. Appel, we look forward to continuing advancement of this promising work and translating this work into a meaningful therapy for patients."

The company's fresh funds will be used to continue work on the company's lead therapeutic program, ALS001, an autologous, expanded Treg cell therapy for amyotrophic lateral sclerosis (ALS) patients , as well as to introduce clinical pipeline candidates targeting Parkinson's disease, Alzheimer's disease, frontal temporal dementia, and more, according to the release.

"Patients with neurodegenerative diseases are in desperate need of transformative therapeutic options; harnessing the neuro-protective effects of Treg cell therapy shows great potential in unlocking a new treatment paradigm and may enable us to revolutionize care for patients with devastating neurodegenerative diseases," says Appel. "We have successfully demonstrated, in a phase 1 trial, the safety and tolerability of autologous infusions of expanded Tregs in ALS patients, with the potential of slowing or halting disease progression. Ongoing studies provide a transformative framework for advanced clinical trials in ALS and other neurodegenerative disorders."

Tribal Capital Markets LLC acted as sole placement agent for the offering, according to the release, and Allele Capital Partners — through Tribal Capital Markets — was responsible for sourcing, investing and executing the $10 million offering.
At a time when the coronavirus crisis is impacting most facets of business, biotech startups are standing up to the virus. Miguel Tovar/University of Houston

UH: How biotech companies are withstanding the pandemic

Houston voices

At a time when the business world is reeling, biotech companies are still hanging on. Many biotech startups have successfully pivoted their entire platforms to focus on coronavirus-related work.

Of course, these companies aren't without their struggles. Clinical trials have come to a pause, finding investors has become more difficult and financing rounds have been surceased.

Even then, there are many biotech startups that have managed to snag government loans via the Paycheck Protection Program among other financial assistance. According to Vivian Doelling, the vice president of emerging company development at the North Carolina Biotechnology Center, COVID-19 has not impacted the bio science industry as much as it has others.

"Some of the smaller biotech companies have pivoted research to be more COVID-centric. This is also true particularly for companies with open platforms or who were developing products in the antiviral space," Doelling told BioSpace, an online biotech publication.

"To add to that, there are research organizations that are receiving more pandemic-centric business from biotech. And that includes clinical trial work," she continued.

Ongoing biotech challenges

It's no surprise that there have been some concerns regarding the delay of clinical trials for products that have nothing to do with coronavirus. It is feared that the delays might create product pipeline problems in the long run. See, companies usually file patent applications before trials even start. So, delays in clinical trials, according to Doelling, "could take up a big chunk of the time in which treatments can have patent exclusivity before generic competition intensifies."

Delays negatively impact smaller biotech startups. These startups' futures typically rely on the success rate of trial outcomes. Any delay in these trials subsequently hurts the small biotech startup. But, even then, the pandemic still doesn't seem to be affecting these startups.

Investment blues

"The expectation is investors are going to hold back more funds than they projected for their portfolio companies. There could be less funding available for new investments," expressed Doelling. However, it is her belief that biotech companies are hot investments right now, and sees new investments on the horizon.

"Investors are cautious at the moment," said Marty Rosendale, the CEO of the Maryland Tech Council, to BioSpace. "They're going to analyze their own portfolio to make sure those companies are solid."

Rosendale, echoing Doelling's investment concerns, says investors want to be more careful right now. They are making it a point to invest less money, which makes it difficult for startups seeking funding.

Keep on keeping on

Many startups are continuing to operate because they've found their rhythm in the virtual workplace. "I have not come across any biotech startup that has closed its doors during the pandemic," Rosendale said. "Sure, some have faced delays and temporarily stopped operations, but overall, haven't heard of any closing for good."

There are a few forces at play when it comes to helping biotech startups stay afloat during the pandemic storm. Landlords are forgiving rent and government loans are helping companies pay employees. "I know of companies that have been out there fundraising since the beginning of the COVID crisis. And they're still out there doing it," Rosendale said. "But I still haven't heard of one company that was forced to end or even delay a round of funding, not one."

------

This article originally appeared on the University of Houston's The Big Idea. Rene Cantu, the author of this piece, is the writer and editor at UH Division of Research.
Formerly competitors and collaborators in the space race, Houston and Huntsville, Alabama, are now moving the needle on biotech. Getty Images

Houston and former space rival are advancing biotech startups

Guest Column

Before scientists flocked to Boston and Silicon Valley; a tech boom occured in the American south that served as a defining moment for the United States: the Space Race.

At the time, two cities were the epicenters of mankind's desire to elevate its existence into the stars. Astronauts controlled the path of rockets that were built in Huntsville, Alabama, while radioing back and forth with Mission Control in Houston, Texas.

Today, the two cities are still aligned, but the final frontier is closer to home. Houston and Huntsville are currently flourishing in the scope of biotechnology, using the innovative research of thousands of scientists, academics, and clinicians to further human knowledge

Houston is the home to the world's largest medical center — the Texas Medical Center, or TMC — and an impressive community developing cutting-edge companies ranging from med to biotech. However, Huntsville is hot on its heels.

Turning an infrastructure initially dedicated to aerospace and aeronautical innovation into an emerging bioscience hub, Huntsville boasts around 50 biotech companies and a genomic research institute. The ecosystem has the highest concentration of STEM workers per capita in the country and is rallied around a collaborative research environment that boasts an impressive tech portfolio, including resident companies like Blue Origin, Facebook, and Google, while still managing to embody southern hospitality.

Mirroring the concerted efforts of the past, my Houston-born startup, Van Heron Labs, has recently taken a leap of faith in moving much of their laboratory operations to Huntsville, while many core team members remain in Houston. Being frustrated with the options for available and affordable lab space in Houston, the completely bootstrapped Van Heron Labs decided to stretch one foot into Alabama while the other stays rooted in the TMC ecosystem.

One positive upside to the shift to remote work in light of the COVID-19 pandemic are new opportunities for company employees, investors, and mentors to be physically separated, while collaborating and retaining productivity. These new dynamics of distance have allowed Van Heron Labs to expand their technical operations while maintaining ties to Houston.

VHL has recently moved into the HudsonAlpha Institute for Biotechnology, where they continue to develop their technology surrounding improved culture media, which hasn't changed much since scientists saw the publication of the first Peanuts comic. Recently, VHL has established a collaborative partnership with fellow Huntsville biotech Foresight Biosciences, and the two will be exploring a wealth of industries together.

Despite the distance, VHL still continues heavy involvement in the Houston ecosystem. My co-founder, Alec Santiago, is the current Director of non-profit, Enventure, and uses his experiences of establishing a biotech startup to help prepare the students around him to do the same.

Additionally, VHL currently has 17 interns, including current and former University of Houston students, Rice University graduate students, and even a local physics PhD. VHL has also long been in talks with companies in TMC, where they have established connections dedicated to growth. Ultimately, they hope to bridge the two cities and help give each access to new ideas, resources, funding, and mentorship.

Too often, emerging biotech startups struggle to get off the ground, and a lack of capital limits what could grow to be great ideas. To foster the growth of innovators around the nation several cities are primed to step in and welcome researchers. Institutions within Alabama's biotech ecosystem are leading the movement.

For just $188 a month, biotech startup companies located at HudsonAlpha campus can enjoy their own office space, and access to tailored programming which includes commercial IP assessments, regular investor forums and pitch opportunities, membership in supporting bioscience organizations, discounted laboratory supplies, as well as help with public relations, human relations, finding mentors, capital, and legal help.

VHL has taken full advantage of these opportunities, while maintaining a presence in Houston, and urges others to do the same. The lifting of our nation's innovators as a whole is a positive movement, and one that can increase access to many bright minds. Just as in the space race, working together regardless of geography can offer unlimited potential and may even take us to an entirely new plane.

------

Rebecca Vaught is the co-founder of Van Heron Labs.
Rebecca Vaught started her biotech company just ahead of COVID-19, but she shares on the Houston Innovators Podcast that it's meant more opportunities than challenges. Photo courtesy of Van Heron Labs

Entrepreneur hopes to bring microbiology into the future with her Houston-based, pandemic-founded startup

HOUSTON INNOVATORS PODCAST EPISODE 40

While startups everywhere are struggling to adapt in the tumultuous times of COVID-19, Rebecca Vaught and her company, having launched just ahead of the pandemic, don't actually know any other way of existing.

After watching some of her friends thrive in Houston's life science ecosystem, she knew Houston was the place she wanted to start the company that she'd been envisioning and plotting for years. She took a chance on the city, moved in, and began Enventure's Biodesign accelerator. The program shutdown as COVID-19 spread, much like other programs, but Vaught wasn't going to let that stop her momentum.

"A lot of people probably would have seen that as the stopping point but that was actually the beginning of the company," Vaught says on the Houston Innovators Podcast. "What it allowed us to do was actually establish the lab and do the hard work."

As Vaught says, the biotech company, Van Heron Labs, is what it is thanks to the pandemic — not just in spite of it.

"While it's been challenging, the pandemic — in a lot of ways — is the only thing we've ever known and it's a lot of reason why the company has taken off and been successful," Vaught says on the show.

She runs the company with co-founder Alec Santiago and a team of 17 interns — all located across the country. Vaught herself is currently residing in Huntsville, Alabama, after struggling to find lab space in Houston. However, the relocation has been a blessing in disguise.

"Both ecosystems are extremely unique and both bring something different to the table," she says. "My next mission, through my lived experience, is igniting or uniting the Houston and Huntsville biotech ecosystems."

On the episode, Vaught explains how the two cities — each representing key parts of space exploration history and burgeoning tech scene — complement each other. She also shares her plans for growth and the need to bring microbiology into the future.

Listen to the full interview below — or wherever you get your podcasts — and subscribe for weekly episodes.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Over $1.4M in prizes awarded at Rice University's student startup competition

RBPC 2021

In its 21st year, the Rice Business Plan Competition hosted 54 student-founded startups from all over the world — its largest batch of companies to date — and doled out over $1.4 million in cash and investment prizes at the week-long virtual competition.

RBPC, which is put on by the Rice Alliance for Technology and Entrepreneurship, took place Tuesday, April 6, to Friday, April 9 this year. Just like 2020, RBPC was virtually held. The competition announced the 54 participating startups last month, and coordinated the annual elevator pitches, a semi-finals round, wildcard round and live final pitches. The contestants also received virtual networking and mentoring.

Earlier this week, Rice Alliance announced the seven student-led startups that then competed in the finals. From this pack, the judges awarded the top prizes. Here's how the finalists placed and what won:

  • SwiftSku from Auburn University, point of sales technology for convenience stores that allows for real time analytics, won first place and claimed the $350,000 grand prize from Goose Capital. The company also won the $50,000 Business Angel Minority Association Prize, the $500 Best Digital Elevator Pitch Prize from Mercury Fund, and the $500 Third Place Anbarci Family People's Choice prize, bringing the company's grand total in cash and investment prizes to $401,000. The company also won the CFO Consulting Prize, a $25,000 in-kind award.
  • AgZen from the Massachusetts Institute of Technology, a pesticide alternative spray and formulation technology company, won the second place $100,000 investment prize (awarded by Finger Interests, Anderson Family Fund, Greg Novak, and Tracy Druce). The startup also won a $300,000 Owl Investment Prize, the $100,000 Houston Angel Network Prize, the $500 Best Energy Elevator Pitch Prize from Mercury Fund, and the $1,500 Third Place Anbarci Family People's Choice prize, bringing the company's grand total in cash and investment prizes to $502,000. The company also won the $30,000 in-kind Polsinelli Energy Prize.
  • FibreCoat GmbH from RWTH Aachen University, a startup with patented spinning technology for the production of inexpensive high-performance composite fibers, won the third place $50,000 investment prize (also awarded by Finger Interests, Anderson Family Fund, Greg Novak, and Tracy Druce). The company also won the $100,000 TiE Houston Angels Prize and the $500 Best Hard Tech Elevator Pitch Prize from Mercury Fund, bringing the company's grand total in cash and investment prizes to $150,500.
  • Candelytics from Harvard University, a startup building the digital infrastructure for 3-D data, won the fourth place $5,000 prize.
  • OYA FEMTECH Apparel from UCLA, an athletic wear company that designs feminine health-focused clothing, won the fifth place $5,000 prize. The company also won the $5,000 Eagle Investors Prize, the $25,000 Urban Capital Network Prize, and the $1,000 Second Place Anbarci Family People's Choice prize, bringing the company's grand total in cash and investment prizes to $36,000.
  • LFAnt Medical from McGill University , an innovative and tech-backed STI testing company, won the sixth place $5,000 prize and the $20,000 Johnson and Johnson Innovation Prize, bringing the company's grand total in cash and investment prizes to $25,000.
  • SimpL from the University of Pittsburgh, an AI-backed fitness software company, won the seventh place $5,000 prize. The company also won the $25,000 Spirit of Entrepreneurship Prize from the Pearland Economic Development Corp., bringing the company's grand total in cash and investment prizes to $30,000.

Some of the competition's participating startups outside of the seven finalists won monetary and in-kind prizes. Here's a list of those.

  • Mercury Fund's Elevator Pitch Prizes also included:
    • Best Life Science $500 Prize to Blue Comet Medical Solutions from Northwestern University
    • Best Consumer $500 Prize to EasyFlo from the University of New Mexico
    • Best Overall $1,000 prize to Anthro Energy from Stanford University
  • The Palo Alto Software Outstanding LivePlan Pitch $3,000 Prize went to LiRA Inc. from the University of North Carolina at Chapel Hill
  • The OFW Law FDA Regulatory Strategy Prize, a $20,000 in-kind award went to Paldara Inc. from Oklahoma State University.
  • The Silver Fox Mentoring Prize, which included $20,000 in kind prizes to three winners selected Ai-Ris from Texas A&M University, BruxAway from the University of Texas, and Karkinex from Rice University as recipients.
  • The first, second, and third place winners also each received the legal service prize from Baker Botts for a total of $20,000 in-kind award.
  • The Courageous Women Entrepreneurship Prize from nCourage — a $50,000 investment prize — went to Shelly Xu Design from Harvard University.
  • The SWPDC Pediatric Device Prize — usually a $50,000 investment divided its prize to two winners to receive $25,000 each
    • Blue Comet Medical Solutions from Northwestern University
    • Neurava from Purdue University
  • TMC Innovation Healthcare Prize awarded a $100,000 investment prize and admission into its accelerator to ArchGuard from Duke University
  • The Artemis Fund awarded its $100,000 investment prize to Kit Switch from Stanford University
The awards program concluded with a plan to host the 22nd annual awards in 2022 in person.

If you missed the virtual programming, each event was hosted live on YouTube and the videos are now available on the Rice Alliance's page.

Houston health center working with new study that uses app to track long-term COVID-19 effects

pandemic innovation

Aided by technology, medical sleuths at the University of Texas Health Science Center at Houston are tracking the long-term effects of COVID-19 as part of a national study.

At the heart of the study is an app that allows patients who have shown COVID-19 symptoms and have been tested for COVID-19 to voluntarily share their electronic health records with researchers. The researchers then can monitor long-term symptoms like brain fog, fatigue, depression, and cardiovascular problems.

UTHealth is one of eight U.S. sites for the INSPIRE trial (Innovative Support for Patients with SARS COV-2 Infections Registry). Researchers are recruiting study participants from Memorial Hermann-Texas Medical Center. They want to expand recruitment to urgent care clinics in the Houston area.

Aside from accessing patients' data through the Hugo Health platform, UTHealth researchers will ask participants to fill out brief follow-up surveys every three months over the course of 18 months. The study complies with the Health Insurance Portability and Accountability Act of 1996 (HIPAA), the federal law that protects patients' information from being disclosed without their knowledge.

"This is a very novel and important study," Dr. Ryan Huebinger, assistant professor in the Department of Emergency Medicine at UTHealth's McGovern Medical School and co-principal investigator of the study, says in a news release.

In a study like this, researchers typically must see a patient in person or at least reach out to them.

"Using this platform is novel because we don't have to schedule additional appointments or ask questions like 'How long were you hospitalized?' – we can automatically see that in their records and survey submissions," Huebinger says.

Mandy Hill, associate professor in the McGovern Medical School's Department of Emergency Medicine and the study's co-principal investigator, says about one-fourth of the people in the study will be local residents who didn't test positive for COVID-19.

"That group will be our control group to be able to compare things like prevalence and risk factors," Huebinger says.

Eligible participants must be at least 18 years old, must have experienced COVID-19 symptoms, and must have been tested for COVID-19 in the past four weeks.

"This is not going to be the last pandemic. The more information we can gather across communities now will give us a leg up when the next pandemic happens," Hill says, "so that we can be more prepared to take steps toward prevention."

Researchers hope to sign up at least 300 study participants in Houston. The entire INSPIRE trial seeks to enroll 4,800 participants nationwide. The study is supposed to end in November 2022.

"There's such great potential for numerous research findings to come out of this study. We could find out if people in Houston are suffering from post-COVID-19 symptoms differently than other parts of the country, whether minorities are more affected by long-hauler symptoms, and if certain interventions work better than others," Hill says.

The U.S. Centers for Disease Control and Prevention (CDC) is financing the study. Aside from UTHealth, academic institutions involved in the research are:

  • University of Texas Southwestern Medical Center in Dallas
  • Rush University Medical Center in Chicago
  • Yale University in New Haven, Connecticut
  • University of Washington in Seattle
  • Thomas Jefferson University in Philadelphia
  • University of California, Los Angeles
  • University of California, San Francisco

5 most popular innovation stories in Houston this week

what's trending

Editor's note: Another week has come and gone, and it's time to round up the top headlines from the past few days. Trending Houston tech and startup news on InnovationMap included innovators to know, a guest column on the challenges of space commercialization, a Q&A with an energy innovation leader, and more.

3 Houston innovators to know this week

This week's roundup of Houston innovators includes Chris Howard of Softeq, Stephanie Hertzog of Sodexo, and Moody Heard of Buildforce. Courtesy photos

In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — oil and gas, tech development, and construction staffing — recently making headlines in Houston innovation. Continue reading.

Houston, we're trying to fix the problem: Aerospace challenges and future exploration

You've heard "it's not rocket science" throughout your life, but but turns out that aerospace exploration — even in 2021 — is still very hard. Photo via Pexels

If there is anything that goes hand in hand so perfectly, it's Houston and Space. Houston is home to the Johnson Space Center, named after former president Lyndon B. Johnson, and is home to revolutionary space research projects and spaceflight training for both crew members and flight controllers. While it's every kid's dream to become an astronaut, have you ever wondered why rocket science is actually so difficult?

Though the space race of the '70s has been over for some time, the new space race — the race to Mars and the commercialization of space tourism — has just started. Elon Musk, Jeff Bezos, and Richard Branson are spearheading the "Billionaire space race." But even with their billions being put into developing spaceports, NASA rocket partnerships, and planning future Mars missions, rocket science is just as difficult to implement as it was the first time around.

So why, even with billions of dollars at their disposal and many companies pushing for more funding, are scientists and engineers still struggling to make rocket travel an everyday thing? Here are some of the countless reasons why rockets science is insanely difficult, no matter how much money you throw at it. Continue reading.

Houston expert: Hospitals are at the forefront of innovation due to pandemic

As we enter year two of the pandemic, the way hospitals function now and in the future is forever changed. Photo via Getty Images

The COVID-19 pandemic has had a drastic effect on every industry throughout the world. Additionally, we have all experienced multiple changes to our daily routine such as schools implementing virtual and hybrid learning while reconfiguring classrooms to promote social distancing and fitness studios closing off every other cardio machine and bench.

But no industry has had to pivot and innovate more than health care, which has been ground zero for the pandemic.

The pace of innovation for hospitals has been at breakneck speed — from the evolution of new treatment protocols to the need to reconfigure physical spaces to support an influx of patients while also promoting a healing environment during this unprecedented time. Continue reading.

Houston CEO talks augmented reality, diversity, how it will all play a role in the energy transition

Stephanie Hertzog, CEO of Houston-based Sodexo, shares how she's embracing diversity and innovation within the energy industry. Photo courtesy of Sodexo

When Stephanie Hertzog first started her role as CEO of Houston-based Sodexo Energy & Resources North America in the fall of 2019, she was on the road every week visiting some of the facility management company's 100 million customers.

"I actually had a conversation with my assistant in early March, and said, 'Okay, our goal is that by April, I not be on the road every week. Let's try to get this to at least every other week,'" she recalls. Shortly after, the world changed, and by March 10 she halted all travel and was forced to lead her company to innovate in more ways than one.

"When we think about innovation, we often think about technology, but we've had to innovate so much in the last 12 months, in how we do everything," she says. "We've really asked a lot of our teams over the last year in regard to having to rethink how they do things and be innovative and adapt." Continue reading.

Houston startup with life-saving innovation receives $2M grant

Houston-based PolyVascular has invented a polymer-based heart valve for children with congenital heart disease. Photo courtesy of TMC Innovation

A $2 million federal grant will enable Houston-based PolyVascular to launch human trials of what it hails as the first polymer-based heart valve for children.

In conjunction with the grant, Dr. Will Clifton has joined the medical device company as chief operating officer. He will oversee the grant as principal investigator, and will manage the company's operations and R&D. Clifton is president and co-founder of Houston-based Enventure, a medical innovation incubator and education hub. He previously was senior director of medical affairs at Houston-based Procyrion, a clinical-stage medical device company.

PolyVascular's Phase II grant came from the Small Business Innovation Research (SBIR) program, which promotes technological projects. Continue reading.

View All Listings